{"protocolSection":{"identificationModule":{"nctId":"NCT01937377","orgStudyIdInfo":{"id":"1160.171"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"GLORIA-AF Registry Program (Phase II/III)","officialTitle":"GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-04-15","type":"ACTUAL"},"completionDateStruct":{"date":"2019-04-15","type":"ACTUAL"},"studyFirstSubmitDate":"2013-09-04","studyFirstSubmitQcDate":"2013-09-04","studyFirstPostDateStruct":{"date":"2013-09-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-02-11","lastUpdatePostDateStruct":{"date":"2021-02-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.\n\nFor administrative purposes the study is divided into three protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, 1160.136 for EU and EEA countries and 1160.171 for Switzerland. The total number of patients enrolled in three protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129."},"conditionsModule":{"conditions":["Stroke","Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":200,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Stroke (hemorrhagic and ischemic, uncertain classification)","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Systemic embolism","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Pulmonary embolism","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Myocardial infarction","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Life-threatening bleeding events","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"All cause death","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Vascular death","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Major bleeding events (including life-threatening bleeding events)","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"composite endpoint: Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"composite endpoint: Stroke, systemic embolism, myocardial infarction and vascular death (vascular composite endpoint)","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"},{"measure":"Transient Ischemic Attack (TIA)","description":"The analysis of the outcome measure is included in study 1160.129","timeFrame":"up to 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1) Patients newly diagnosed with non-valvular atrial fibrillation (NVAF) at risk for stroke.\n\nFurther inclusion criteria apply\n\nExclusion criteria:\n\n1. Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;\n2. Patients who have received more than 60 days of vitamin K antagonist (VKA) treatment in their lifetime;\n3. AF with a generally reversible cause;\n4. Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (for example, a VKA) is indicated.\n\nFurther exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"patients with non-valvular AF","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Boehringer Ingelheim","affiliation":"Boehringer Ingelheim","role":"STUDY_CHAIR"}],"locations":[{"facility":"University Hospital Basel","city":"Basel","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"CHUV - Centre hospitalier universitaire vaudois","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"Cardiocentro Ticino","city":"Lugano","zip":"CH-6900","country":"Switzerland","geoPoint":{"lat":46.01008,"lon":8.96004}},{"facility":"Kantonsspital St.Gallen","city":"St. Gallen","zip":"9007","country":"Switzerland","geoPoint":{"lat":47.42391,"lon":9.37477}},{"facility":"Arzte Zentrum Eigerpark, Urtenen-Schonbuhl","city":"Urtenen-Schonbuhl","zip":"3322","country":"Switzerland","geoPoint":{"lat":47.02226,"lon":7.49969}}]},"referencesModule":{"references":[{"pmid":"35876418","type":"DERIVED","citation":"Ding WY, Lane DA, Gupta D, Huisman MV, Lip GYH; GLORIA-AF Investigators. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. J Am Heart Assoc. 2022 Aug 2;11(15):e026410. doi: 10.1161/JAHA.122.026410. Epub 2022 Jul 25."},{"pmid":"35488127","type":"DERIVED","citation":"Ding WY, Calvert P, Gupta D, Huisman MV, Lip GYH; GLORIA-AF Investigators. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. Clin Res Cardiol. 2022 Sep;111(9):1057-1068. doi: 10.1007/s00392-022-02022-1. Epub 2022 Apr 29."},{"pmid":"33912651","type":"DERIVED","citation":"Azar RR, Ragy HI, Kozan O, El Khuri M, Bazergani N, Marler S, Teutsch C, Ibrahim M, Lip GYH, Huisman MV. Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program. Int J Cardiol Heart Vasc. 2021 Apr 10;34:100763. doi: 10.1016/j.ijcha.2021.100763. eCollection 2021 Jun."},{"pmid":"33338644","type":"DERIVED","citation":"Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, Thompson M, Lip GYH, Olshansky B; GLORIA-AF Investigators. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic J Cardiol. 2021 Mar-Apr;62(2):152-157. doi: 10.1016/j.hjc.2020.11.009. Epub 2020 Dec 15."},{"pmid":"29653649","type":"DERIVED","citation":"Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIA-AF Investigators. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J. 2018 Apr;198:55-63. doi: 10.1016/j.ahj.2017.08.018. Epub 2017 Aug 31."}],"seeAlsoLinks":[{"label":"Results of this study are submitted together with study 1160.129","url":"https://clinicaltrials.gov/ct2/show/results/NCT01468701?term=1160.129&draw=2&rank=1"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}